Bayer Confirms 2025 Financial Outlook Amid Market Challenges
I'm PortAI, I can summarize articles.
Bayer AG has confirmed its upgraded financial outlook for 2025, citing strong performance in its agricultural and pharmaceuticals divisions. However, the Consumer Health division faces market challenges, with revised sales growth expectations of minus 1 to plus 1 percent. The company anticipates special items in full-year Group EBITDA to be between minus 4.0 to minus 3.5 billion euros, and in Group EBIT between minus 3.0 to minus 2.5 billion euros, reflecting increased litigation provisions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments